{"data":{"issuanceinfo":{"industrycode":"204005","industry":"醫療保健","ipoprice":{"ceiling":"20.150","floor":"17.800"},"ipodate":{"start":"2020-05-12 00:00:00","end":"2020-05-15 00:00:00"},"minimumcapital":"10176.52","subscribed":"551.32","marketcap":"74.43億","H_marketcap":"--","pe":"--","codesrate":"10.00","link":"https://staticpdf.iqdii.com/stockdata/notice/09939/2020/2020051200014_c.pdf","ipopricing":"20.150","resultdate":"2020-05-21 00:00:00","enddate":"2020-05-15 00:00:00","listeddate":"2020-05-22 00:00:00","issuenumber":"9234.75萬","issuenumberhK":"4617.40萬","issuenumberother":"4617.35萬","grayprice":"21.30","sponsors":"華泰金融控股(香港)有限公司","raisemoney":"174750.00萬","use":"1、約42%所得款項凈額（約734.0百萬港元）分配至我們的其中一種核心產品普克魯胺的開發及商業化；\n2、約28%所得款項凈額（約489.3百萬港元）分配至我們的其中一種核心產品福瑞他恩的開發及商業化；\n3、約4%所得款項凈額（約69.9百萬港元）分配至開發我們的臨床階段在研藥物ALK-1；\n4、約4%所得款項凈額（約69.9百萬港元）分配至開發我們的臨床階段在研藥物迪拓賽替；\n5、約4%所得款項凈額（約69.9百萬港元）分配至開發我們的臨床階段在研藥物GT1708F（Hedgehog/SMO抑制劑）；\n6、約2%所得款項凈額（約35.0百萬港元）分配至其他臨床研究項目；\n7、約6%所得款項凈額（約104.8百萬港元）分配至我們臨床前階段在研藥物的研發；\n8、約10%所得款項凈額（約174.7百萬港元）分配至我們的營運資金及一般企業用途。","shares":500,"leadagent":"華泰金融控股(香港)有限公司,瑞士銀行香港分行,中國國際金融香港證券有限公司,招銀國際融資有限公司,華興證券(香港)有限公司,海通國際證券有限公司,建銀國際金融有限公司,中國光大證券(香港)有限公司,浦銀國際融資有限公司,富途證券國際(香港)有限公司,阿爾法國際證券(香港)有限公司","bookrunners":"華泰金融控股(香港)有限公司,瑞士銀行香港分行,中國國際金融香港證券有限公司,招銀國際融資有限公司,華興證券(香港)有限公司,海通國際證券有限公司,建銀國際金融有限公司,中國光大證券(香港)有限公司","coordinator":"華泰金融控股(香港)有限公司,瑞士銀行香港分行,中國國際金融香港證券有限公司","firstDayOpen":"20.15","IsEiio":0,"Interestdays":6,"PENote":"按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。","OverAllotment":"有","StabilizingManager":"瑞士銀行香港分行","code":"E09939","name":"開拓藥業－Ｂ","fullname":"開拓藥業有限公司"},"institutioninfo":{"principaloffice":"中國江蘇省蘇州市蘇州工業園區星湖街218號生物納米園C4幢401室","registrars":"香港中央證券登記有限公司","registrarstel":"(852) 2862 8628","chairman":"童友之","secretary":"陳潔,楊靜文","telephone":"(86512) 6295 6307  ","substantialshareholders":"KT International Investment Limited(13.82%),KG Development Limited(13.82%),Real Able Limited(7.58%)","principalactivities":"公司是中國一家臨床階段新藥開發商，專注于自主研發潛在同類首創及同類最佳癌癥藥物及其他AR相關疾病藥物。","website":"http://www.kintor.com.cn"},"managerinfo":[{"managername":"童友之","post":"主席、行政總裁兼執行董事","rankno":1},{"managername":"郭創新","post":"非執行董事","rankno":2},{"managername":"陸剛","post":"非執行董事","rankno":3}],"investorinfo":[{"institutionname":"珠海格力金融投資管理有限公司","shareholding":"37,696,500.0","percentage":40.82,"ReleaseDate":"2020-11-22 00:00:00","relatedparty":"珠海格力集團有限公司","subsidiary":["珠海格力金融投資管理有限公司"],"InverstorType":"公司"},{"institutionname":"Cherry Cheeks HK Limited","shareholding":"2,692,500.0","percentage":2.92,"ReleaseDate":"2020-11-22 00:00:00","relatedparty":"HL Partners II L.P.","subsidiary":["Cherry Cheeks HK Limited"],"InverstorType":"公司"},{"institutionname":"Foresight Orient Global Superior Choice SPC","shareholding":"1,923,000.0","percentage":2.08,"ReleaseDate":"2020-11-22 00:00:00","relatedparty":"東方資產管理(香港)有限公司","subsidiary":["Foresight Orient Global Superior Choice SPC","Orient Sun Rise Global Superior Choice SPC"],"InverstorType":"基金"},{"institutionname":"Highlight Medical Limited","shareholding":"1,923,000.0","percentage":2.08,"ReleaseDate":"2020-11-22 00:00:00","relatedparty":"Highlight Capital Partners I L.P.","subsidiary":["Highlight Medical Limited"],"InverstorType":"公司"}],"TotalShareholdingPercentage":47.9},"result":1,"Version":"4.5.190802.46408","ElapsedMilliseconds":10}